18:30 , Nov 30, 2018 |  BC Week In Review  |  Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

Founded by former executives of HCV companies that scored big exits, Antios Therapeutics Inc. (Atlanta, Ga.) raised a $25 million series A round to develop a cure for HBV. Antios' co-founders include CEO Abel De...
23:06 , Nov 27, 2018 |  BC Extra  |  Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

Founded by former executives of HCV companies that scored big exits, Antios Therapeutics Inc. raised a $25 million series A round to develop a cure for HBV. Antios' co-founders include CEO Abel De La Rosa...
17:02 , Jul 27, 2018 |  BC Week In Review  |  Company News

Milligan, Martin leaving Gilead

Gilead Sciences Inc. (NASDAQ:GILD) said President and CEO John Milligan will step down at year end. The company's board is searching for a successor. Milligan has been at Gilead for 28 years. He became CEO...
01:05 , Jul 26, 2018 |  BC Extra  |  Company News

Milligan, Martin leaving Gilead

Gilead Sciences Inc. (NASDAQ:GILD) said President and CEO John Milligan will step down at year end. The company's board is searching for a successor. Milligan has been at Gilead for 28 years. He became CEO...
15:44 , Oct 6, 2017 |  BC Week In Review  |  Financial News

Roivant to invest $116.4M in Arbutus

Arbutus Biopharma Corp. (NASDAQ:ABUS) said Roivant Sciences GmbH (Basel, Switzerland) agreed to invest up to $116.4 million through the purchase of 1.2 million convertible preferred shares at a $7.13 conversion price, which represents a 15%...
22:35 , Oct 2, 2017 |  BC Extra  |  Financial News

Roivant to invest $116.4M in Arbutus

Arbutus Biopharma Corp. (NASDAQ:ABUS) said Roivant Sciences GmbH (Basel, Switzerland) agreed to invest up to $116.4 million through the purchase of convertible preferred shares at a $7.13 conversion price, which represents a 15% premium to...
18:03 , Sep 1, 2017 |  BC Week In Review  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
00:56 , Aug 29, 2017 |  BC Extra  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
00:42 , Aug 12, 2017 |  BioCentury  |  Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...